StreetAlpha.app
Home › Stocks › UPB

Upstream Bio, Inc. (UPB)

Healthcare
$2.10
▼ −2.33%
LAST CLOSE · NOV 17

Upstream Bio develops verekitug, an experimental antibody drug for severe asthma, nasal polyps and COPD. It last closed at $2.10 on Nov 17, down 2.33% on the day. In the past 30 days there were 1 dark pool print totaling $282K, the largest $282K.

AI Auto Pilots
Is UPB in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$2.9M
+2.5% vs a year ago
Net income
−$163.9M
−5712.3% margin
EPS (diluted)
−$3.01
−128.2% vs a year ago
Free cash flow
−$168.4M
−5867.2% margin
Valuation
Market cap
$115.1M
54.8M shares
P/E
–
No P/E while losing money
Price to sales
40.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$47.4M
At Sep 30
Shareholder equity
$234.0M
Shares outstanding
54.8M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $2.4M$2.4MFY2023FY2024: $2.4M$2.4MFY2024FY2025: $2.9M$2.9MFY2025

From UPB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated UPB in the past 90 days, not enough for a consensus
Average 12-month target
$18.00
▲ 757.1% upside

Based on 1 analyst who set a price target on UPB in the past 90 days. The average target is $18.00, with a high of $18.00 and a low of $18.00, compared with the last close of $2.10.

Low $18.00Avg $18.00High $18.00
Blue marker: last close $2.10
Highest target$18.00
Average target$18.00
Lowest target$18.00
Latest rating changes
HC Wainwright & Co.Target lowered
Nov 11Buy$36 → $18
HC Wainwright & Co.Reiterated
Sep 2Buy$36
JP MorganTarget raised
Aug 14Hold$8 → $9
Truist SecuritiesMaintained
Aug 12Buy$25
JP MorganDowngrade
Jun 12Hold$8
DateFirmActionRatingPrice target
Nov 11HC Wainwright & Co.Target loweredBuy$36 → $18
Sep 2HC Wainwright & Co.ReiteratedBuy$36
Aug 14JP MorganTarget raisedHold$8 → $9
Aug 12Truist SecuritiesMaintainedBuy$25
Jun 12JP MorganDowngradeHold$8
Loading…

Technical Analysis

UPB · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 44% below its 20 day and 94% below its 50 day average. It is 262% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the 52 week low at $2.00, and the nearest resistance the Pivot R1 at $2.20.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 17.4%/day
Key levels
$33.6852 week high+1503.8%
$7.60200 day average+261.9%
$5.50100 day average+161.9%
$4.0850 day average+94.3%
$3.84Swing high (Nov 4)+82.9%
$3.0320 day average+44.3%
$2.20Pivot R1+4.8%
$2.10Pivot+0.0%
$2.10Last close
$2.0052 week low−4.8%
$2.00Pivot S1−4.8%
Indicators
RSI (14)27.63Oversold below 30Oversold
MACD-0.41Below its signal lineBearish
Stochastic5.2Near the bottom of its rangeOversold
ADX (14)36.6Trending down
Williams %R-94.8Oversold below −80, overbought above −20Oversold
CCI (20)-199.2Oversold below −100, overbought above 100Oversold
Rate of change−38.0%Change over 10 sessionsBearish
ATR (14)$0.36Typical daily range, 17.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for UPB

What happened before

See how UPB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in UPB in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$282K
Largest print
$282K
Loading…

UPB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●73 buying vs 79 selling
  • ▼Held by funds -4.5 pts
  • ▼Funds holding -14
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding135149−9.4%
In funds' top 10220.0%
Held by funds87.7%92.3%−4.5 pts
New / increased18 / 5537 / 65−28.4%
Reduced / sold out48 / 3128 / 28+41.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See UPB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether UPB is in one of them and how their past UPB trades turned out.

UPB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered UPB in an article yet. Here's the latest on the wider market.

About Upstream Bio

Upstream Bio is a biotechnology company based in Waltham, Massachusetts, that develops treatments for inflammatory diseases. Its main candidate, verekitug, is a monoclonal antibody that blocks the receptor for a protein called TSLP, which plays a role in immune responses. The company is testing verekitug in clinical trials for severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease. The drug is not yet approved, and its intended patients are people with these lung and airway conditions.

Headquarters
Waltham, MA